Originally published In Press as doi:10.1074/jbc.M207410200 on September 21, 2002
J. Biol. Chem., Vol. 277, Issue 48, 46364-46373, November 29, 2002
Identification of a Novel Family of Cell-surface
Proteins Expressed in Human Vascular Endothelium*
Ruey-Bing
Yang
,
Chi Kin Domingos
Ng
,
Scott M.
Wasserman
,
Steven D.
Colman§,
Suresh
Shenoy§,
Fuad
Mehraban§,
László G.
Kömüves
,
James E.
Tomlinson
, and
James N.
Topper
¶
From the
Department of Cardiovascular Research,
Millennium Pharmaceuticals, Inc.,
South San Francisco, California 94080 and the
§ Department of Collaborative Research, CuraGen
Corporation, New Haven, Connecticut 06511
Received for publication, July 23, 2002, and in revised form, September 20, 2002
 |
ABSTRACT |
Vascular endothelial cells (EC) play a key role
in a variety of pathophysiologic processes, such as angiogenesis,
inflammation, cancer metastasis, and vascular diseases. As part of a
strategy to identify all genes expressed in human EC, a full-length
cDNA encoding a potential secreted protein harboring 10 epidermal
growth factor (EGF)-like domains and one CUB domain at the carboxyl
terminus (termed, SCUBE1 for Signal
peptide-CUB-EGF-like domain containing protein
1) was identified. SCUBE1 shares homology with several protein families, including members of the fibrillin and Notch families, and the anticoagulant proteins, thrombomodulin and protein C. SCUBE1 mRNA is found in several highly vascularized tissues such as
liver, kidney, lung, spleen, and brain and is selectively expressed in
EC by in situ hybridization. SCUBE1 is a secreted glycoprotein that can form oligomers and manifests a stable association with the cell surface. A second gene encoding a homologue (designated SCUBE2) was also identified and is expressed in EC as well as other
cell types. SCUBE2 is also a cell-surface protein and can form a
heteromeric complex with SCUBE1. Both SCUBE1 and SCUBE2 are rapidly
down-regulated in EC after interleukin-1
and tumor necrosis
factor-
treatment in vitro and after lipopolysaccharide injection in vivo. Thus, SCUBE1 and SCUBE2 define an
emerging family of human secreted proteins that are expressed in
vascular endothelium and may play important roles in development,
inflammation, and thrombosis.
 |
INTRODUCTION |
Vascular endothelium
(EC),1 the single layer of
cells located at the interface between tissue and blood, plays an
essential role in the maintenance of normal vascular physiology.
Dysfunction of this cell type can lead to vascular diseases such as
hypertension and atherosclerosis (1). The functional phenotype of EC is dynamically responsive to a variety of physiologic and pathophysiologic stimuli that include proinflammatory cytokines, growth factors, bacterial products, as well as biomechanical forces (2, 3). Many of
these functions are mediated by proteins selectively expressed on the
surface of ECs. For example, tissue factor expressed on the surface of
EC in response to activation serves as a cofactor for factor VIIa to
activate factor X and factor IX in the coagulation cascade (4).
Conversely, the anticoagulant protein thrombomodulin is an EC surface
molecule that binds thrombin, thereby activating protein C that in the
presence of protein S degrades factor Va and VIIIa (5, 6). E-selectin
is an EC-selective adhesion molecule that is rapidly induced on
inflamed EC and plays a critical role in leukocyte recruitment (7). In
addition, organ-selective EC surface molecules have been functionally
identified in several tissues, and an endothelial marker responsible
for tumor homing to the lungs has been identified (8-11). To begin to
understand the repertoire of human EC surface molecules, we have
combined comprehensive library sequencing with transcriptional
profiling to identify EC-selective genes (12).
Approximately 100,000 cDNA fragments derived from EC were
sequenced, and these sequences were then merged with public data bases
to obtain ~10,000 independent gene assemblies putatively expressed in
EC. To validate their endothelial expression, these genes were then
represented on customized oligonucleotide microarrays (13),
together with all of the non-redundant human genes from public data
bases (12). Competitive hybridizations were performed utilizing both
endothelial and non-endothelial cell types, and these analyses revealed
~400 genes that were uniquely expressed in EC. These included the
majority of genes known to be expressed in an EC-selective pattern,
such as angiotensin-converting enzyme, acetylated low density
lipoprotein receptor, E-selectin, Tie-2, VEGFR2 (KDR), von Willebrand
factor, NOS3, CD31, endothelin, VE-cadherin, EphB4, and ephrin-B2, and
many uncharacterized genes.
One full-length cDNA identified by these approaches encoded a
potential secreted protein harboring a signal peptide at the amino
terminus followed by 10 EGF-like repeats and 1 CUB domain at the
carboxyl terminus (termed SCUBE1 for Signal
peptide-CUB- EGF-like domain containing protein
1). Interestingly, when overexpressed, SCUBE1 protein is
not only secreted but is also tethered on the cell surface. Likewise, a
second human gene encoding a homologue (designated SCUBE2) was also
identified and appears to be expressed in EC and displayed onto cell
surface in overexpressing 293T cells. SCUBE1 and SCUBE2, when singly or
coexpressed, can manifest homo- and heterotypic interactions.
Furthermore, SCUBE1 and SCUBE2 expression is down-regulated in EC after
IL-1
and TNF-
treatment in vitro and after LPS
injection in vivo, suggesting a possible role of the SCUBE
gene family in the inflammatory response. Previous work has described
the apparent mouse homologues of Scube1 and
Scube2 (14, 15). Based solely on their expression in a
variety of embryonic tissues, it was proposed that the Scube
gene family may play roles in development; however, no adult expression
data were reported. Our results indicate that SCUBE1 and SCUBE2 define an emerging secreted and cell-surface protein family that is expressed in human vascular endothelium.
 |
EXPERIMENTAL PROCEDURES |
In Situ Hybridization--
The details of tissue preparation and
in situ hybridization have been described earlier (16-18).
Following the manufacturer's protocol, digoxigenin-labeled antisense
and sense riboprobes were synthesized from DNA templates (nucleotides
2241-2529) using reagents supplied by Roche Molecular Biochemicals.
Sectioning, pretreatment of the sections, and hybridization of the
probes were done under strict RNase-free conditions. All reagents were
prepared using diethyl pyrocarbonate-treated distilled water. 15-µm
thick sections were collected on positively charged slides and dried at
55 °C overnight. The sections were deparaffinized and rehydrated in Histosolve and ethanol and rinsed in diethyl pyrocarbonate-treated distilled water. The sections were treated at room temperature with 0.2 N HCl (20 min), 1.5% H2O2 (15 min), 0.3% Triton X-100 (15 min) followed by proteinase K treatment at
37 °C (30 min). The sections then were washed with triethanolamine
buffer followed by acetylation with acetic anhydride. Following
prehybridization in 2× SSC, containing 50% formamide at 37 °C (1 h), the sections were air-dried at room temperature. Sections were
hybridized with the probes diluted in hybridization solution (2× SSC,
containing 50% formamide, 10× Denhardt's, 0.001% SDS, 10 mM Tris, pH 7.4, 0.005% sodium pyrophosphate, and 500 µg/ml yeast tRNA) at 55 °C overnight. Following hybridization, the
sections were washed with 4× SSC (twice for 15 min) and 2× SSC (twice
for 15 min). The sections then were treated with RNase A at 37 °C
(30 min) followed by stringency washes in 2× SSC at 37 °C (15 min),
0.1× SSC at 42 °C (40 min), and finally in 0.1× SSC at room
temperature (twice for 15 min). The sections were washed with maleate
buffer (30 min) and then blocked with 10 mM Tris buffer, pH
7.6, containing 500 mM NaCl, 4% bovine serum albumin,
0.5% cold-water fish skin gelatin, and 0.05% Tween 20. The sections
were then incubated with anti-digoxigenin antibody, conjugated to
peroxidase (Roche Molecular Biochemicals), for 1 h. The signal was
amplified using TSA-Plus kit (PerkinElmer Life Sciences), and the
signal was detected with Vector Blue substrate (Vector Laboratories,
Burlingame, CA). Following incubation with substrate the sections were
dehydrated in ethanol and Histosolve and coverslipped. Hybridization
with the sense control probe did not result in detectable signal,
indicating the specificity of hybridization.
Microscopy--
Slides were observed with an Olympus BX50
microscope (Olympus, Inc., Melville, NY), using DIC illumination. The
microscope was equipped with a Nikon DXM1200 digital camera (Technical
Instruments, San Francisco, Burlingame, CA). Digitized images
(1280 × 1024-pixel resolution) were acquired using ACT-1 software
(Nikon, Melville, NY). Images were resized, cropped, and assembled
using Photoshop version 6.0 (Adobe Systems, San Jose, CA). Apart from
equalizing the background intensities, no other digital modifications
of the original digital images were carried out.
Identification of the Full-length Clones of Human SCUBE1 and
SCUBE2--
To capture the diverse repertoire of genes expressed in
EC, multiple libraries from EC under various stimuli (such as
shear-stressed, proinflammatory cytokine-treated) were generated and
normalized using methods described previously (19). Approximately
100,000 cDNA fragments were sequenced, and these sequences were
then merged with public data bases to obtain ~10,000 EC gene
independent assemblies. To validate their endothelial expression, these
genes were then represented on custom oligonucleotide microarrays (13),
together with all of non-overlapping human genes from public data bases (12). Competitive hybridizations were performed among both endothelial and non-endothelial cells. Clustering analyses revealed ~400 genes that were uniquely expressed in EC. One cDNA fragment encoding multiple copies of EGF-like domains was identified and subsequently mapped onto human chromosome 22q13. Based on gene prediction, two
oligonucleotides (5'-CAG CGG GGC CCG CAT TGA GCA TGG GCG CGG-3' and
5'-CCC GGT TAT TTG TAG GGC CGC AGG AAC CGA-3') were used to amplify the
entire open reading frame by PCR from a mixture of human cDNA
libraries. The amplified SCUBE1 full-length cDNA was cloned into
pCR2.1 (Invitrogen) and confirmed by sequencing. The clone containing
full-length SCUBE2 was obtained from OriGene Technologies (Rockville,
MD). Full-length sequences for SCUBE1 were deposited into
GenBankTM with accession number AF525689, and the SCUBE2
sequence is the same as NM_020974 (except nucleotides 1287 to 1526 are
spliced out in the clone we used).
Northern Blot Analysis--
The human Northern blot was
purchased from Clontech and hybridized with a
radiolabeled human SCUBE1 cDNA probe (nucleotides 2077-2851) per
the manufacturer's protocol.
Construction of Expression Plasmids--
The epitope-tagged
versions of SCUBE1 or SCUBE2 were constructed in the following
expression vectors. The pcDNA4/Myc-His (Invitrogen) was used to add
a Myc tag to the carboxyl terminus of SCUBE1 containing endogenous
signal peptide. The pSecTag2 (Invitrogen) including Ig
-chain leader
sequence was used to add a Myc tag at the carboxyl terminus of SCUBE2.
The pFLAG-CMV-1 (Sigma) was used to include a FLAG tag at the amino
terminus of target protein.
Cell Culture and Transfection--
Human embryonic kidney 293T
cells were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum, 100 µg/ml penicillin, and
100 µg/ml streptomycin. Cells were seeded in 6-well plates overnight
before transfection. The transfection was performed by using FuGENE 6 reagent (Roche Molecular Biochemicals). The total amount of DNA was
kept constant in all transfections by supplementing empty vector DNA.
Human umbilical vein endothelial cells (HUVEC) were cultured as
described previously (20).
Immunoprecipitation and Western Blot Analyses--
Transfected
cells were washed once with PBS and lysed for 15 min on ice in 0.5 ml
of lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
25 mM sodium pyrophosphate, 1 mM
-glycerophosphate, 1 mM Na3VO4,
1 µg/ml leupeptin). Lysates were clarified by centrifugation at
4 °C for 15 min at 10,000 × g. Cells lysates were
incubated with 1 µg of indicated antibody and 20 µl of 50% (v/v)
protein A-agarose (Pierce) for 2 h with gentle rocking. After
three washes with lysis buffer, precipitated complexes were solubilized
by boiling in Laemmli sample buffer, fractionated by SDS-PAGE, and
transferred to polyvinylidene difluoride membranes. The membranes were
blocked with PBS, pH 7.5, containing 0.1% gelatin and 0.05% Tween 20 and were blotted with the indicated antibodies. After two washes, the
blots were incubated with horseradish peroxidase-conjugated goat
anti-mouse IgG (The Jackson Laboratories) for 1 h. After washing
the membranes, the reactive bands were visualized with the enhanced
chemiluminescence system (Amersham Biosciences).
Subcellular Fractionation--
Transfected cells were washed
with PBS and lysed in hypotonic lysis buffer (10 mM Tris,
pH 7.4, 10 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 2 mM EDTA). After incubation
for 30 min on ice, cells were homogenized with 80 strokes in a tight
fitting Dounce homogenizer. The lysed cells were then centrifuged at
1,000 × g (30 min, 4 °C), and the supernatant taken
and further centrifuged at 100,000 × g (30 min,
4 °C) to obtain the cytosolic (S100) and membrane (P100) fractions.
The P100 fraction was washed once with hypotonic lysis buffer,
resuspended in 0.1 M Na2CO3, pH 12, sonicated briefly, and then incubated on ice for 30 min. Samples were
centrifuged again at 100,000 × g for 30 min to give
washed fractions S100' and pellets P100'.
FACS Analysis--
Transfected cells were collected and
suspended in PBS, 2% bovine serum albumin in a volume of 0.25 ml. A
total of 1 µg of purified anti-FLAG M2 antibody and fluorescein
isothiocyanate-conjugated goat anti-mouse secondary antibody (1:100
dilution, Jackson ImmunoResearch Laboratories, West Grove, PA) was
added sequentially; each were incubated for 45 min on ice. FACS
analyses were performed with a FACScan (BD Biosciences).
Lipopolysaccharide (LPS) Administration--
LPS
(Escherichia coli serotype O111:B4) was purchased from Sigma
and dissolved in PBS at concentration of 1 mg/ml. LPS solution (5 mg/kg) or PBS was injected intraperitoneally into a group of three
C67BL/6 mice, and at the indicated time points (3, 6, 24, and 48 h
post-injection), the kidneys of these animals were harvested, washed in
sterile cold PBS, and frozen in liquid nitrogen.
RNA Isolation, Semi-quantitative Reverse Transcription (RT)-PCR,
and TaqMan Analyses--
Total RNA was prepared from cultured cells or
harvested animal kidneys using TRIzol reagents (Invitrogen).
First-strand cDNA synthesis using SuperScript II reverse
transcriptase (Invitrogen) was prepared on 5 µg of total RNA.
One-tenth of the first-strand cDNA reaction was used for each PCR
as template. Alternatively, premade first-strand cDNAs from human
tissues (Clontech, Palo Alto, CA) were used as PCR
template. Semi-quantitative RT-PCR primers specific for human SCUBE1
and SCUBE2 were as follows: SCUBE1-f2, AGT GTT CTC CAG GCT TCT
TCT; SCUBE1-r2, CAG TGC TGG TTT TTG CAG TGT; SCUBE2-f2, AGA CCC
CAG AAG CTT GGA ATA; SCUBE2-r2, TCC CCT CCA CAT CTT CTG TTT. GAPDH
primers were obtained from Clontech. Real time
TaqMan PCR analyses were performed using Applied Biosystems PRISM 7700 Sequence Detection System. Normalization was performed using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels as
controls in parallel TaqMan reactions. The 5' and 3' primers and a
fluorescence-labeled probe were designed as follows: SCUBE1 5' primer,
AAC ACA CGG GTA CCG CCT CTT; SCUBE1 3' primer, GTA TTG TAG TGG TGT CCG
GGA GA; SCUBE1 probe, CCA GGA CTG CGA GGC CAA AGT GCA T; SCUBE2 5'
primer, CAG GAT TGT GAA ACC CGA GTT C; SCUBE2 3' primer, CGG ATA CAT
CGG TGT GTG GTG; SCUBE2 probe, TGC TCG CCT GGG CAT TTC TAC AAC A; GAPDH
primer-probe was purchased from BioSource International (Camarillo, CA).
 |
RESULTS |
Identification of a Gene Highly Expressed in EC--
The
endothelial origin of a SCUBE1 cDNA fragment identified by genomic
approaches was confirmed by in situ hybridization (Fig. 1). It was expressed in the luminal
endothelial cells of the human umbilical vessels (Fig. 1a).
Furthermore, localization of this gene to ECs was validated in
cynomolgus monkey brain (Fig. 1b), lung (Fig. 1,
c and d), and kidney (Fig. 1, e and
f). In addition to endothelial expression in artery and
vein, this gene is also expressed in microvascular endothelial cells in
a variety of tissues (Fig. 1, b-f, and data not shown).

View larger version (135K):
[in this window]
[in a new window]
|
Fig. 1.
Validation of the endothelial
expression of a SCUBE1 cDNA fragment by in situ
hybridization. The endothelial origin of one SCUBE1 cDNA
fragment identified by genomic approach was confirmed by a highly
sensitive in situ hybridization assay (16-18). Localization
of this gene to the EC (blue stain) was demonstrated in
human umbilical cord artery (a, inset,
vein), monkey brain (b), lung (c and
d), and kidney (e and f).
|
|
To obtain the full-length cDNA of this gene, the original cDNA
fragment was mapped to human genomic sequence (www.ensembl.org) and
was found to be localized on chromosome 22q13, where a human gene was
predicted based on its homology to mouse Scube1 (14). Two
oligonucleotides, based on this gene prediction, were used to amplify
the entire open reading frame from human cDNAs. This cDNA
contains an open reading frame of 2964 nucleotides and encodes a
polypeptide of 988 amino acids (Fig.
2a). Hydropathy (21) and
protein family analyses (22) predict one amino-terminal signal peptide
(22 amino acids) followed by 10 EGF-like repeats and a CUB domain (Fig.
2). There is an apparent spacer region located between the 9th and 10th
EGF-like repeats (Fig. 2b). This domain structure is
identical to that of mouse Scube1, therefore, this human
orthologue was designated SCUBE1 to be consistent with the literature
(14). Mature SCUBE1 is predicted to contain 966 amino acids with
calculated molecular mass of 106 kDa.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 2.
Primary sequence and domain
structure of human SCUBE1. a, primary sequence of
the 988-amnio acid human SCUBE1 as deduced by the full-length cDNA
clone. The signal peptide, EGF-like repeats, and CUB domain are
marked or underlined. Potential glycosylation
sites are indicated by dots. The margins of two deletion
constructs in this study, D1 and D2, are marked. The estimated mature
mass is 105,553 Da, and the pI is 6.7. b,
hydrophobicity plot and domain structure of human SCUBE1. The plot was
generated according to the coefficients proposed by Kyte and Doolittle
(21). The region marked with the thick line indicates the
putative signal peptide (see a). The lower panel
shows the domain structure of SCUBE1 protein. In addition to the
EGF-like repeats and the CUB domain, a spacer region is located between
the 9th and 10th EGF-like repeat. FL, full-length;
D1, deletion mutant 1; D2, deletion mutant 2;
E, EGF-like repeats; CUB, CUB domain;
SP, signal peptide.
|
|
Tissue Distribution of Human SCUBE1 Transcript--
A Northern
blot containing poly(A)+-enriched mRNA (2 µg) from a
variety of human adult tissues was hybridized with a human SCUBE1
cDNA radiolabeled probe. The expression level of the SCUBE1 transcripts was highest in liver, kidney, lung, and small intestine, followed by brain, colon, and spleen. The expression in remaining tissues was very low or undetectable (Fig.
3). Expression of SCUBE1 in several
highly vascular tissues, such as liver, kidney, and lung, is consistent
with the endothelial origin of SCUBE1 demonstrated by in
situ hybridization (Fig. 1). The size of the primary transcript for SCUBE1 (4 kb) is consistent with both the predicted and cloned full-length cDNA (Fig. 2).

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 3.
Northern blot analysis of
poly(A)+ mRNA from various human tissues for
SCUBE1. Two micrograms of poly(A)-enriched mRNA from various
human adult tissues were hybridized with SCUBE1 cDNA radiolabeled
probe. The SCUBE1 probe identified an mRNA species of 4.0 kb. The
lower panel shows the same blot hybridized with -actin
probe as a control.
|
|
SCUBE1 Is a Secreted and Cell-associated Protein--
Because
human SCUBE1 protein has a putative signal peptide at the amino
terminus and because human SCUBE1 protein contains 10 EGF-like repeats
that are found in many extracellular matrix proteins (ECM) (23, 24), we
examined whether the SCUBE1 protein is a secretory and/or ECM protein.
For this purpose, recombinant SCUBE1 protein was expressed by means of
transient expression in human embryonic kidney 293T cells. The Myc
epitope tag was added at the carboxyl terminus for the detection of the
recombinant protein. Two days after transfection, the culture
supernatants were collected, and cells were detached from dishes by
EDTA treatment, and residual ECM proteins were extracted with Laemmli
buffer. Samples collected from these three fractions were subjected to Western blot analyses using anti-Myc antibody. As shown in Fig. 4a, human SCUBE1 protein was
detected in the conditioned cell culture medium (Medium) and
in cells (Cell) but was not detected in the ECM fraction
(Matrix) or in fractions from the control vector-transfected
cells. These data demonstrate that the SCUBE1 protein is a secreted and
cell-associated protein.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Human SCUBE1 can be a secreted protein.
a, expression of SCUBE1 containing the endogenous
signal peptide results in a secreted protein. 293T cells were
transfected with an expression vector encoding human SCUBE1 Myc-tagged
at the carboxyl terminus (SCUBE1.Myc). Forty eight hours
post-transfection, conditioned medium was collected, and then cells
were detached with PBS/EDTA. Extracellular matrix on the culture dish
was extracted with Laemmli sample buffer. Samples from conditioned
culture medium (Medium), cell lysates (Cell), and
the extracellular matrix (Matrix) were separated by 4-20%
SDS-PAGE and transferred to polyvinylidene difluoride membranes.
Recombinant SCUBE1 proteins were detected by Western blotting with
anti-Myc antibody. b, secreted SCUBE1 is the same size as
cell-associated form. 293T cells were transfected with the expression
vector encoding dual FLAG- and Myc-tagged SCUBE1 at the amino and
carboxyl terminus (Flag.SCUBE1.Myc). Two days after transfection,
samples from conditioned culture medium (Medium), cell
lysates (Cell), and the extracellular matrix
(Matrix) were separated by 4-20% SDS-PAGE and transferred
to polyvinylidene difluoride membranes. Recombinant SCUBE1 proteins
were detected by Western blotting with anti-FLAG M2 or anti-Myc
antibody. c, secreted SCUBE1 is not a proteolytic product.
Conditioned culture medium from cells transfected with dual-tagged
Flag.SCUBE1.Myc was immunoprecipitated with anti-FLAG M2 antibody, and
then the precipitates were immunoblotted with indicated antisera.
IP, immunoprecipitation; WB, Western blot.
|
|
Because the CUB domain was recently described in two novel members of
the platelet-derived growth factor (PDGF) family that require
proteolytic activation (25-28), we tested whether secreted SCUBE1
could be subject to proteolytic cleavage. A dual epitope-tagged SCUBE1
with FLAG and Myc tags added to the amino and carboxyl terminus,
respectively, was transiently expressed in 293T cells. Forty eight
hours post-transfection, samples from conditioned medium, cells, and
ECM were individually immunoblotted with anti-FLAG or anti-Myc
antibodies. As shown in Fig. 4b, the molecular weight of
detected SCUBE1 protein is identical either by anti-FLAG or anti-Myc
antibodies. These results suggest that the secreted SCUBE1 protein does
not undergo further proteolytic processing. Consistent with this
finding, the dual-tagged SCUBE1 protein immunoprecipitated by FLAG
antibody from cell culture conditioned medium (Medium) showed the identical molecular size when blotted either with anti-FLAG or Myc antibodies separately (Fig. 4c).
Human SCUBE1 Is N-Glycosylated--
The molecular size of
expressed SCUBE1 in 293T cells is about 130 kDa, slightly larger than
the predicted size of the full-length SCUBE1 protein. Because human
SCUBE1 possesses six putative N-linked glycosylation motifs
(Fig. 2a), we hypothesized that SCUBE1 is subject to
post-translational modification by glycosylation. Thus, we examined
whether tunicamycin, an inhibitor of N-glycosylation, affected the molecular size of the protein. As shown in Fig.
5, tunicamycin treatment of cells
resulted in a reduction in the molecular size of the precursor form of
the SCUBE1 protein (lanes 2 and 5), indicating
that the majority of SCUBE1 is glycosylated when expressed in 293T
cells. To determine the contribution of the six putative
N-linked glycosylation sites in the SCUBE1 protein, we
compared the molecular size of the carboxyl-terminal deletion mutants
(D1 and D2) with or without tunicamycin treatment. As shown in Fig. 5,
the precursor form of mutant D1 (in which the carboxyl-terminal CUB
domain is deleted) was detected at 110 kDa without tunicamycin
(lane 3), whereas the protein size was shifted to a faster
migrating band by treatment with tunicamycin (lane 6),
indicating that the mutant D1 is glycosylated. However, tunicamycin treatment did not change the apparent molecular size of the precursor form of mutant D2 (lanes 4 and 7) (in which five
of six putative N-linked glycosylation motifs in the protein
are deleted) (Fig. 2b). Taken together, these data
demonstrated that SCUBE1 is N-glycosylated at multiple sites
within the carboxyl-terminal region.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 5.
Human SCUBE1 is a glycosylated protein.
293T cells were transfected with the expression vector encoding
full-length FLAG-tagged or deletion mutants (D1 and D2) of human
SCUBE1. Transfected cells were cultured in the absence ( ) or in the
presence of tunicamycin (5 µg/ml) for 24 h. Cell lysates from
each culture were analyzed by Western blotting with anti-FLAG M2
antibody.
|
|
Homomeric Interactions of SCUBE1 Proteins--
Because
families of secreted growth factors or cytokines are often capable of
forming dimeric or higher ordered complexes (29, 30), and because
SCUBE1 is a secretory protein, we hypothesized that oligomeric forms of
SCUBE1 protein may exist. We constructed cDNAs encoding FLAG- or
Myc-tagged SCUBE1 proteins, and we examined their association by
co-immunoprecipitation assays from both singly and co-transfected 293T
cells (Fig. 6a). Lysates of
these cells were immunoprecipitated with the anti-Myc monoclonal
antibody, and then the precipitates were analyzed by immunoblotting
with anti-FLAG monoclonal antibody. A 130-kDa immunoreactive band
recognized by anti-FLAG antibody was observed in the anti-Myc
immunoprecipitates from cells co-expressing SCUBE1.Myc and Flag.SCUBE1
proteins but not from cells transfected with individual tagged
constructs alone (Fig. 6a). Likewise, the reciprocal
immunoprecipitation of Flag.SCUBE1 results in the co-precipitation
of SCUBE1.Myc (Fig. 6a). We did not observe an association
between SCUBE1 and IL-1R1, suggestion specificity of the homomeric
interactions between SCUBE1 proteins (Fig. 6a). Furthermore,
homomeric association of SCUBE1 proteins appears to require
co-expression and is not an artifact formed only after cell lysis,
because a mixture of lysates containing separately expressed tagged
proteins is not sufficient for complex formation in this heterologous
expression system (data not shown). These results demonstrate that
human SCUBE1 proteins are capable of forming oligomeric complexes when
co-expressed.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 6.
Homo-oligomerization of human SCUBE1 in
transfected 293T cells. a, homomeric interaction
of SCUBE1 proteins. The differential tagged constructs, Flag-SCUBE1 or
SCUBE1.Myc, were singly or co-transfected in 293T cells. As a control,
SCUBE1.Myc was expressed together with FLAG-tagged IL-1 receptor 1 (Flag.IL-1R1). Immunoprecipitation (IP) and Western blot
(WB) were performed using antisera as indicated. Experiments
were performed three times with similar results. b,
EGF-like repeats are sufficient for SCUBE1 homotypic associations.
Full-length (FL) SCUBE1.Myc was expressed together with
Flag.SCUBE1-FL, SCUBE1-D1, or SCUBE1-D2 (see Fig. 3) by transient
transfection. Detergent lysates were immunoprecipitated with anti-Myc
antibody and then immunoblotted with anti-FLAG M2 antibody to determine
the associated proteins. Cell lysates were also immunoblotted to
examine the protein expression levels.
|
|
We then used carboxyl-deletion mutants (D1 and D2) to characterize
which domains of SCUBE1 are necessary for SCUBE1 oligomerization. Two
deletion constructs, FLAG-tagged SCUBE1-D1 or SCUBE1-D2 and full-length
(FL) SCUBE1, were transiently co-expressed with SCUBE1.Myc in 293T
cells (Fig. 6b). Immunoprecipitation of SCUBE1.Myc resulted in the co-precipitation of Flag.SCUBE1-D1 or Flag.SCUBE1-D2 (Fig. 6b). These data suggest that the first nine copies of the
EGF-like repeats in the SCUBE1-D2 mutant protein are sufficient for
SCUBE1 complex formation.
Human SCUBE1 Is a Peripheral Membrane Protein--
Because the
majority of expressed SCUBE1 protein appears cell-associated (Fig.
4a), we next determined its subcellular distribution by
biochemical fractionation. 293T cells transiently expressing FLAG-tagged SCUBE1 proteins were lysed in hypotonic buffer, and low and
high speed centrifugation was performed to obtain a membrane fraction
(P100) and a cytoplasmic fraction (S100). Subcellular distribution of
SCUBE1 protein was monitored by anti-FLAG immunoblotting. As shown in
Fig. 7, most of the Flag.SCUBE1 protein
was partitioned into the P100 membrane fraction, suggesting that SCUBE1
is membrane-bound. The presence of a small amount (less than 10%) of
SCUBE1-D2 mutant protein in the cytosol may be due to some aberrant
processing of this mutant or simply be a nonspecific effect of
overexpression.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 7.
Membrane association of human SCUBE1
protein. 293T cells were transfected with the expression plasmids
encoding indicated FLAG-tagged proteins. Two days after transfection,
cells were collected and homogenized. Samples of supernatant
were centrifuged at 100,000 × g for 30 min to
give soluble fractions (S100) and pellets (P100
membrane fraction). Pellets were further resuspended in original
volumes of homogenization buffer with 0.1 M
Na2CO3, pH 12, sonicated briefly, and then
incubated on ice for 30 min. Samples were centrifuged again at
100,000 × g for 30 min to give washed fractions
S100' and pellets P100'. Each fraction was
subjected to SDS-PAGE and immunoblot analysis using anti-FLAG M2
antibody.
|
|
To assess the physical nature of SCUBE1 interaction with the plasma
membrane, the P100 membrane fraction was treated with conditions that
solubilize peripheral membrane proteins. All three forms of SCUBE1
protein were stripped off the membrane when incubated with 0.1 M Na2CO3, pH 12 (Fig. 7,
S100'), whereas the Toll-like receptor-2 (TLR2), a single
membrane-spanning receptor (31), was not released from the washed
membranes (Fig. 7, P100'). These data indicate that
membrane-bound SCUBE1 behaves like a peripheral membrane protein.
Spacer Region Is Critical for SCUBE1 Protein Secretion and
Cell-surface Expression--
Because expression of FL SCUBE1 can
result in a secreted protein, we examined whether or not the carboxyl
domain plays a role in protein secretion. Two carboxyl-terminal
deletion constructs, SCUBE1-D1 or SCUBE1-D2, were transiently expressed
in 293T cells. The conditioned culture medium was collected and
subjected to Western blotting analysis using anti-FLAG antibody. As
shown in Fig. 8a, SCUBE1-D1
mutant (deleting the CUB domain) was expressed and secreted into the
conditioned medium like the FL protein, whereas the SCUBE1-D2 mutant
protein was not secreted (Fig. 8a). These data suggest that
the spacer region, located between the 9th and the 10th EGF-like motif,
is essential for SCUBE1 protein secretion, at least when overexpressed
in 293T cells.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 8.
The spacer region is critical for the
secretion and surface expression of SCUBE1. a, the
space region is required for SCUBE1 secretion. 293T cells were
transfected with the expression plasmids encoding indicated FLAG-tagged
SCUBE1 and IL-1R1 or JNK1 constructs as controls. Two days after
transfection, conditioned culture medium was concentrated and separated
on SDS-PAGE and Western-blotted with anti-FLAG M2 antibody.
b, the spacer region is essential for cell-surface
tethering of recombinant SCUBE1. The expression constructs
Flag-SCUBE1-FL (top), -D1 (middle), or -D2
(bottom) were singly or co-transfected with SCUBE1.Myc
plasmid in 293T cells. Twenty four hours post-transfection, cells were
detached and stained with anti-FLAG M2 antibody as described under
"Experimental Procedures." Experiments were performed twice with
similar results.
|
|
To confirm that SCUBE1 is a secreted, peripheral membrane protein, we
examined SCUBE1 cell-surface expression by flow cytometry analysis in
intact cells. As shown in Fig. 8b, we confirmed the cell-surface expression of wild-type SCUBE1-FL or SCUBE1-D1 proteins (top and middle) by FACS analysis, whereas the
SCUBE1-D2 deletion mutant is defective in cell-surface targeting when
individually expressed (bottom). However, because SCUBE1-D2
mutant protein is capable of forming complexes with wild-type protein
(Fig. 6b) and because wild-type SCUBE1-FL is a cell-surface
protein (Fig. 8b), we next tested if co-expression with FL
protein can restore the cell-surface targeting phenotype of SCUBE1-D2
mutant. Indeed, as shown in Fig. 8b (bottom),
co-expression of wild-type SCUBE1.Myc resulted in the expression and
targeting of SCUBE1-D2 mutant onto the cell surface as determined by
flow cytometry.
Identification of a Second Member of SCUBE Family--
By
utilizing homology searches, we identified a homologous human gene
encoding a protein with identical domain structure to that of SCUBE1,
designated SCUBE2. The mouse orthologue (Scube2) of this
human gene was recently described (15). To compare the tissue
expression patterns of human SCUBE1 and SCUBE2, each gene was examined
by semi-quantitative PCR in a panel of human tissue cDNA (Fig.
9). Consistent with the Northern blot
analysis (Fig. 3), SCUBE1 mRNA expression was restricted to few
highly vascularized tissues such as liver, lung, and kidney (Fig. 9).
In contrast, SCUBE2 transcript was expressed in a broad spectrum of
human tissues (Fig. 9). Likewise, SCUBE2 message, but not SCUBE1, was
also observed in several non-endothelial human primary cell types such
as fibroblasts and renal mesangial cells (Fig.
10).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 9.
Tissue distribution of SCUBE gene family
determined by RT-PCR analyses. Human tissue cDNAs were
amplified with primers specific for SCUBE1 or SCUBE2. Amplification of
GAPDH was performed as a positive control. Sk., skeletal;
PBL, peripheral blood leukocyte.
|
|

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 10.
Down-regulation of the SCUBE1 and SCUBE2
messages upon the treatment of proinflammatory cytokines in HUVEC.
Several human primary cells and HUVEC treated with IL-1 and TNF-
for 6 and 24 h were submitted for RT-PCR analyses. AOSMC, aortic
smooth muscle cell.
|
|
The co-expression of the closely-related SCUBE1 and SCUBE2 mRNAs in
cultured ECs (Fig. 10) raises the question of whether these proteins
interact. To ascertain the formation of heteromeric complexes, differentially epitope-tagged SCUBE1 and SCUBE2 constructs were singly
or co-transfected into 293T cells, and immunoprecipitations were
performed. When Flag.SCUBE2 is co-expressed with either SCUBE1.Myc or
SCUBE2.Myc, immunoprecipitation with FLAG antibody co-precipitates both
proteins (Fig. 11). This interaction is
not seen with tagged IL-1R1, indicating the specificity of this assay
(Fig. 11).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 11.
Hetero- and homo-oligomerizations of SCUBE2
in transfected 293T cells. Indicated expression plasmids were
singly or co-transfected in 293T cells. Detergent lysates of each
transfection were subjected to immunoprecipitation (IP) and
immunoblotting (WB) using antibodies as indicated.
Experiments were performed twice with similar results. The double bands
seen for the Flag.SCUBE1 and Flag.IL-1R1 are due to the
glycosylation of these proteins.
|
|
Down-regulation of the SCUBE Transcripts by Proinflammatory
Cytokines in Vitro and LPS in Vivo--
Because vascular ECs are
important cellular targets for the actions of proinflammatory cytokines
(32), we determined whether or not expression of the endothelial
Scube gene family could be altered in response to
proinflammatory cytokines. Cultured HUVEC were exposed to IL-1
or
TNF-
for 6 and 24 h, respectively. Total RNAs isolated from
cytokine-treated HUVEC were subjected to semi-quantitative RT-PCR to
measure the expression level of SCUBE1 and SCUBE2. As shown in Fig. 10,
SCUBE1 transcript was significantly down-regulated by both cytokine
treatments with IL-1
stimulation, demonstrating a more rapid
response than that of TNF-
treatment. In contrast, SCUBE2 expression
was only modestly depressed in response to 24 h of TNF-
treatment.
To validate further this observation in vivo, we
investigated whether the expression of SCUBE1 and SCUBE2 was affected
by systemic LPS administration in C57BL/6 mice. A group of animals (n = 3) was sacrificed after intraperitoneal injection
of either LPS (5 mg/kg) or PBS vehicle at 3, 6, 24, and 48 h.
Kidneys were collected and subjected to real time TaqMan analyses. As
shown in Fig. 12, SCUBE1 RNA levels
were dramatically down-regulated 3 h after injection of LPS and
then quickly returned to untreated levels. SCUBE2 expression was also
depressed by LPS injection, although with slightly slower kinetics,
reaching the lowest level at 6 h postinjection and then recovering
to untreated control levels over a 48-h period. These results indicate
that both the Scube1 and Scube2 genes are
dynamically responsive to inflammatory stimuli in vivo.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 12.
Depression of the Scube
gene family expression upon the treatment of LPS in mice. A
group of C57/BL6 mice (n = 3) were sacrificed after
intraperitoneal injection of either LPS at 5 mg/kg or PBS vehicle at
indicated time points. Kidneys were collected and submitted for the
TaqMan analyses as described under "Experimental Procedures."
|
|
 |
DISCUSSION |
In this report we have identified a family of secreted proteins
expressed in human vascular endothelial cells. Members of this gene
family were named as SCUBE, based on their unique domain structures
which consist of one Signal peptide, one CUB
domain, and multiple EGF-like repeats (Fig. 2). SCUBE1
appears to be expressed selectively in endothelium. In situ
hybridization demonstrated SCUBE1 expression in the EC lining the
arteries, veins, and the microvessels of all organs examined (Fig. 1).
Consistent with this finding, the highest levels of SCUBE1 expression
are found in vascularized tissues (Fig. 3). In contrast, SCUBE2 is
expressed in EC but is also found in additional cell types such as
fibroblasts and renal mesangial cells and is expressed in a wide range
of tissues (Figs. 9 and 10). Based on these disparate expression
patterns, the SCUBE proteins may mediate distinct sets of functions in
these various cell types and tissues.
The EGF-like repeat, a six-cysteine conserved motif, is found in many
classes of proteins such as secreted growth factors, transmembrane
receptors, adhesion molecules, signaling proteins, and components of
the ECM (24). On the other hand, the CUB domain, which was named based
on the first three identified proteins of this family, i.e.
Complement proteins C1r/C1s, Uegf (sea urchin fibropellins), and Bmp1, is thought to mediate
protein-protein interaction and has been found in a more limited set of
proteins involved in developmental processes such as embryogenesis or
organogenesis (33). A number of proteins with a role in embryonic
development or immune responses have been identified that contain both
the EGF-like and the CUB domains. These include Drosophila
tolloid (34) and the mammalian tolloid-like proteins BMP1
(procollagen C proteinase) (35) and mTll (36), sea urchin
fibropellins (37), the complement proteins C1s and C1r (37, 38), and the serum glycoprotein attractin (39, 40). Mouse Scube1 had been reported to be expressed prominently in the developing gonad, nervous system, somites, surface ectoderm, and limb buds (14), whereas
mouse Scube2 was restricted to the embryonic neuroectoderm in mouse embryos ranging from 7.5 to 12.5 days post-coitum (15). Based
on these expression patterns, it was hypothesized that the Scube gene family may play roles in the development of these
organ systems (14, 15). In our studies, we have observed
pan-endothelial expression of Scube1 in mouse 17.5 days
post-coitum embryos by in situ hybridization (data not
shown). These results are consistent with the pan-endothelial
expression of SCUBE1 in the adult (Fig. 1). Thus, it appears that the
endothelial restricted expression of this gene is acquired relatively
late in development and persists into adulthood. These data suggest
that this protein may have critical roles in both development and
endothelial/vascular biology in the adult.
Based on cellular and biochemical studies, we have demonstrated that
SCUBE1 proteins are capable of forming homomeric complexes and that the
first nine EGF-like repeats are sufficient to maintain these
interactions in 293T cells (Fig. 6). Because of the presence of both
SCUBE1 and SCUBE2 in EC, we further investigated whether heteromeric
complexes could form. These studies have indicated that both SCUBE1 and
SCUBE2 can form homo- and heteromeric complexes with each other (Figs.
6 and 11). These data suggest that SCUBE1 and SCUBE2 may have related
functions in EC.
The molecular mechanisms by which SCUBE proteins target to the cell
surface and associate with the membrane remain unclear at present. We
originally hypothesized that a short hydrophobic stretch within the CUB
domain (Fig. 2b) may be responsible for the cell-surface
association. However, this was disproved because the SCUBE1-D1 deletion
mutant, which lacks the carboxyl CUB domain, still retains its ability
to be secreted and cell surface-associated (Figs. 7 and 8).
Surprisingly, the spacer region, located between the 9th and 10th
EGF-like repeats, appears essential for SCUBE1 protein secretion and
cell-surface targeting, because the SCUBE1-D2 deletion mutant, which is
missing this spacer region as well as the rest of the carboxyl portion,
is defective in secretion and cell-surface expression (Fig. 8).
Interestingly, the defective phenotype of SCUBE1-D2 mutant protein can
be effectively rescued by co-expression with FL SCUBE1 (Fig.
8b). This is consistent with the finding that SCUBE1-D2
mutant protein is still capable of forming a complex with the wild-type
SCUBE1-FL protein (Fig. 6b) and suggests that this physical
interaction with the wild-type protein may be playing a role in the
"re-targeting" to cell surface (Fig. 8b). SCUBE1 is a
glycoprotein (Fig. 5), and the deletion of multiple N-linked
glycosylation sites in SCUBE1-D2 deletion mutant resulted in a loss of
cell surface association (Fig. 8b). Thus, it may be that
yet-to-be-identified lectins or mucin-like proteins with
carbohydrate-binding capacity could serve as receptor(s) or binding
site(s) for SCUBE proteins on EC. Alternatively, the EGF-like repeats
of SCUBE proteins may form heteromeric complexes with other
cell-surface proteins containing EGF-like repeats, much like the
interactions seen in the transmembrane Notch receptors and their
ligands, Delta and Serrate (41).
Data base searches identified members of the fibrillin family of ECM
proteins as having significant homology to SCUBE proteins, based
largely on their multiple EGF-like repeats. Interestingly, mutations in
the fibrillin-1 gene cause Marfan syndrome, which is characterized in
part by significant vascular abnormalities (42). Another protein family
that contains multiple EGF-like repeats is the latent TGF-
-binding
protein (LTBP) family. Four different LTBP homologues, LTBPs 1-4, have
been characterized (43, 44). LTBPs function to enhance secretion and
stability of the latent TGF-
complex, ensure correct folding of
TGF-
, and target the latent TGF-
complex to the ECM of certain
cells and tissues for storage or to the cell surface where activation takes place (43, 45, 46). To examine if SCUBE1 could have a similar
role, we tested whether SCUBE proteins, like LTBPs, are capable of
binding growth factors or cytokines. Flag.SCUBE1 was co-expressed
individually with PDGF-D, IL-8, or IL-17F, all of which are expressed
in or have functions in EC (27, 28, 47, 48). In our primary studies,
Flag.SCUBE1 proteins were capable of forming stable complexes with
PDGF-D and IL-17F but not with IL-8 (data not shown). Although the full
significance of this interaction is currently unknown, this observation
suggests that SCUBE1 proteins may potentially function to modulate the expression or function of certain growth factors.
An additional interesting domain feature of SCUBE1 is that it contains
six Ca2+-binding EGF-like repeats (49), a motif found in
many coagulation factors (e.g. fVII, IX, X, and XII) (50,
51) and anticoagulant proteins (e.g. thrombomodulin and
protein C) (52, 53). As shown in Figs. 10 and 12, SCUBE1 and SCUBE2
transcripts were down-regulated in EC either by inflammatory cytokines
in vitro or LPS injection in vivo. This is
reminiscent of the suppression of EC cell-surface thrombomodulin and
protein C expression, in response to IL-1
, TNF-
, and LPS
treatment (54-58). These data strongly suggest that SCUBE proteins are
involved in the inflammatory responses and raise the interesting
hypothesis that they may be modulators of thrombosis or coagulation.
In summary, we have identified a novel family of human EC-expressed
secreted proteins termed SCUBE proteins. SCUBE1 appears to represent a
novel Pan-endothelial expressed protein, and both SCUBE1 and SCUBE2 are
found in EC. Although the precise functions are currently unknown,
their unique structures, combined with their patterns of expression and
modulation by inflammatory stimuli, point to potential roles in
development, inflammation, and thrombosis.
 |
ACKNOWLEDGEMENTS |
We thank Keith Abe and Francis Deguzman for
excellent technical assistance in LPS administration and tissue
collections. We also thank Drs. Neill Giese and Li Fang for providing
the expression plasmids for PDGF-C and PDGF-D, and Dr. David
R. Phillips for reading the manuscript and suggestions.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
650-246-7333; Fax: 650-244-9270; E-mail: Jamie.Topper@mpi.com.
Published, JBC Papers in Press, September 21, 2002, DOI 10.1074/jbc.M207410200
 |
ABBREVIATIONS |
The abbreviations used are:
EC, endothelial
cells;
EGF, epidermal growth factor;
TNF-
, tumor necrosis
factor-
;
IL, interleukin;
LPS, lipopolysaccharide;
HUVEC, human
umbilical vein endothelial cells;
PBS, phosphate-buffered saline;
FACS, fluorescence-activated cell sorter;
RT, reverse transcription;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
ECM, extracellular matrix
proteins;
PDGF, platelet-derived growth factor;
FL, full length;
TGF-
, transforming growth factor-
;
LTBP, latent
TGF-
-binding protein.
 |
REFERENCES |
| 1.
|
Cines, D. B.,
Pollak, E. S.,
Buck, C. A.,
Loscalzo, J.,
Zimmerman, G. A.,
McEver, R. P.,
Pober, J. S.,
Wick, T. M.,
Konkle, B. A.,
Schwartz, B. S.,
Barnathan, E. S.,
McCrae, K. R.,
Hug, B. A.,
Schmidt, A. M.,
and Stern, D. M.
(1998)
Blood
91,
3527-3561[Free Full Text]
|
| 2.
|
Topper, J. N.,
and Gimbrone, M. A., Jr.
(1999)
Mol. Med. Today
5,
40-46[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Topper, J. N.,
Cai, J.,
Falb, D.,
and Gimbrone, M. A., Jr.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10417-10422[Abstract/Free Full Text]
|
| 4.
|
Rapaport, S. I.,
and Rao, L. V.
(1992)
Arterioscler. Thromb.
12,
1111-1121[Medline]
[Order article via Infotrieve]
|
| 5.
|
Thompson, E. A.,
and Salem, H. H.
(1986)
J. Clin. Invest.
78,
13-17[Medline]
[Order article via Infotrieve]
|
| 6.
|
Esmon, C. T.
(1995)
FASEB J.
9,
946-955[Abstract]
|
| 7.
|
Rosen, S. D.,
and Bertozzi, C. R.
(1994)
Curr. Opin. Cell Biol.
6,
663-673[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Johnson, R. C.,
Zhu, D.,
Augustin-Voss, H. G.,
and Pauli, B. U.
(1993)
J. Cell Biol.
121,
1423-1432[Abstract/Free Full Text]
|
| 9.
|
Arap, W.,
Kolonin, M. G.,
Trepel, M.,
Lahdenranta, J.,
Cardo-Vila, M.,
Giordano, R. J.,
Mintz, P. J.,
Ardelt, P. U.,
Yao, V. J.,
Vidal, C. I.,
Chen, L.,
Flamm, A.,
Valtanen, H.,
Weavind, L. M.,
Hicks, M. E.,
Pollock, R. E.,
Botz, G. H.,
Bucana, C. D.,
Koivunen, E.,
Cahill, D.,
Troncoso, P.,
Baggerly, K. A.,
Pentz, R. D., Do, K. A.,
Logothetis, C. J.,
and Pasqualini, R.
(2002)
Nat. Med.
8,
121-127[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Pasqualini, R.,
and Ruoslahti, E.
(1996)
Nature
380,
364-366[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Rajotte, D.,
Arap, W.,
Hagedorn, M.,
Koivunen, E.,
Pasqualini, R.,
and Ruoslahti, E.
(1998)
J. Clin. Invest.
102,
430-437[Medline]
[Order article via Infotrieve]
|
| 12.
|
Yang, R. B.,
Tomlinson, J. E.,
Conley, P. B.,
Hart, M. J.,
Komuves, L. G.,
Ziman, M.,
Lum, P. Y.,
Roberts, C.,
and Topper, J. N.
(2002)
Physiologist
45,
76
|
| 13.
|
Hughes, T. R.,
Mao, M.,
Jones, A. R.,
Burchard, J.,
Marton, M. J.,
Shannon, K. W.,
Lefkowitz, S. M.,
Ziman, M.,
Schelter, J. M.,
Meyer, M. R.,
Kobayashi, S.,
Davis, C.,
Dai, H., He, Y. D.,
Stephaniants, S. B.,
Cavet, G.,
Walker, W. L.,
West, A.,
Coffey, E.,
Shoemaker, D. D.,
Stoughton, R.,
Blanchard, A. P.,
Friend, S. H.,
and Linsley, P. S.
(2001)
Nat. Biotechnol.
19,
342-347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Grimmond, S.,
Larder, R.,
Van Hateren, N.,
Siggers, P.,
Hulsebos, T. J.,
Arkell, R.,
and Greenfield, A.
(2000)
Genomics
70,
74-81[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Grimmond, S.,
Larder, R.,
Van Hateren, N.,
Siggers, P.,
Morse, S.,
Hacker, T.,
Arkell, R.,
and Greenfield, A.
(2001)
Mech. Dev.
102,
209-211[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Komuves, L. G.,
Hanley, K.,
Lefebvre, A. M.,
Man, M. Q., Ng, D. C.,
Bikle, D. D.,
Williams, M. L.,
Elias, P. M.,
Auwerx, J.,
and Feingold, K. R.
(2000)
J. Invest. Dermatol.
115,
353-360[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Komuves, L. G.,
Feren, A.,
Jones, A. L.,
and Fodor, E.
(2000)
J. Histochem. Cytochem.
48,
821-830[Abstract/Free Full Text]
|
| 18.
|
Stelnicki, E. J.,
Komuves, L. G.,
Kwong, A. O.,
Holmes, D.,
Klein, P.,
Rozenfeld, S.,
Lawrence, H. J.,
Adzick, N. S.,
Harrison, M.,
and Largman, C.
(1998)
J. Invest. Dermatol.
110,
110-115[Medline]
[Order article via Infotrieve]
|
| 19.
|
Shimkets, R. A.,
Lowe, D. G.,
Tai, J. T.,
Sehl, P.,
Jin, H.,
Yang, R.,
Predki, P. F.,
Rothberg, B. E.,
Murtha, M. T.,
Roth, M. E.,
Shenoy, S. G.,
Windemuth, A.,
Simpson, J. W.,
Simons, J. F.,
Daley, M. P.,
Gold, S. A.,
McKenna, M. P.,
Hillan, K.,
Went, G. T.,
and Rothberg, J. M.
(1999)
Nat. Biotechnol.
17,
798-803[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
DiChiara, M. R.,
Kiely, J. M.,
Gimbrone, M. A.,
Lee, M. E.,
Perrella, M. A.,
and Topper, J. N.
(2000)
J. Exp. Med.
192,
695-704[Abstract/Free Full Text]
|
| 21.
|
Kyte, J.,
and Doolittle, R. F.
(1982)
J. Mol. Biol.
157,
105-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Sonnhammer, E. L.,
Eddy, S. R.,
and Durbin, R.
(1997)
Proteins
28,
405-420[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Prigent, S. A.,
and Lemoine, N. R.
(1992)
Prog. Growth Factor Res.
4,
1-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Davis, C. G.
(1990)
New Biol.
2,
410-419[Medline]
[Order article via Infotrieve]
|
| 25.
|
Li, X.,
Ponten, A.,
Aase, K.,
Karlsson, L.,
Abramsson, A.,
Uutela, M.,
Backstrom, G.,
Hellstrom, M.,
Bostrom, H., Li, H.,
Soriano, P.,
Betsholtz, C.,
Heldin, C. H.,
Alitalo, K.,
Ostman, A.,
and Eriksson, U.
(2000)
Nat. Cell Biol.
2,
302-309[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Gilbertson, D. G.,
Duff, M. E.,
West, J. W.,
Kelly, J. D.,
Sheppard, P. O.,
Hofstrand, P. D.,
Gao, Z.,
Shoemaker, K.,
Bukowski, T. R.,
Moore, M.,
Feldhaus, A. L.,
Humes, J. M.,
Palmer, T. E.,
and Hart, C. E.
(2001)
J. Biol. Chem.
276,
27406-27414[Abstract/Free Full Text]
|
| 27.
|
Bergsten, E.,
Uutela, M., Li, X.,
Pietras, K.,
Ostman, A.,
Heldin, C. H.,
Alitalo, K.,
and Eriksson, U.
(2001)
Nat. Cell Biol.
3,
512-516[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
LaRochelle, W. J.,
Jeffers, M.,
McDonald, W. F.,
Chillakuru, R. A.,
Giese, N. A.,
Lokker, N. A.,
Sullivan, C.,
Boldog, F. L.,
Yang, M.,
Vernet, C.,
Burgess, C. E.,
Fernandes, E.,
Deegler, L. L.,
Rittman, B.,
Shimkets, J.,
Shimkets, R. A.,
Rothberg, J. M.,
and Lichenstein, H. S.
(2001)
Nat. Cell Biol.
3,
517-521[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Davies, D. R.,
and Wlodawer, A.
(1995)
FASEB J.
9,
50-56[Abstract]
|
| 30.
|
Sun, P. D.,
and Davies, D. R.
(1995)
Annu. Rev. Biophys. Biomol. Struct.
24,
269-291[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Yang, R. B.,
Mark, M. R.,
Gray, A.,
Huang, A.,
Xie, M. H.,
Zhang, M.,
Goddard, A.,
Wood, W. I.,
Gurney, A. L.,
and Godowski, P. J.
(1998)
Nature
395,
284-288[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Mantovani, A.,
Bussolino, F.,
and Dejana, E.
(1992)
FASEB J.
6,
2591-2599[Abstract]
|
| 33.
|
Bork, P.,
and Beckmann, G.
(1993)
J. Mol. Biol.
231,
539-545[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Finelli, A. L.,
Bossie, C. A.,
Xie, T.,
and Padgett, R. W.
(1994)
Development
120,
861-870[Abstract]
|
| 35.
|
Li, S. W.,
Sieron, A. L.,
Fertala, A.,
Hojima, Y.,
Arnold, W. V.,
and Prockop, D. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5127-5130[Abstract/Free Full Text]
|
| 36.
|
Clark, T. G.,
Conway, S. J.,
Scott, I. C.,
Labosky, P. A.,
Winnier, G.,
Bundy, J.,
Hogan, B. L.,
and Greenspan, D. S.
(1999)
Development
126,
2631-2642[Abstract]
|
| 37.
|
Delgadillo-Reynoso, M. G.,
Rollo, D. R.,
Hursh, D. A.,
and Raff, R. A.
(1989)
J. Mol. Evol.
29,
314-327[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Leytus, S. P.,
Kurachi, K.,
Sakariassen, K. S.,
and Davie, E. W.
(1986)
Biochemistry
25,
4855-4863[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Duke-Cohan, J. S.,
Tang, W.,
and Schlossman, S. F.
(2000)
Adv. Exp. Med. Biol.
477,
173-185[Medline]
[Order article via Infotrieve]
|
| 40.
|
Duke-Cohan, J. S., Gu, J.,
McLaughlin, D. F., Xu, Y.,
Freeman, G. J.,
and Schlossman, S. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
11336-11341[Abstract/Free Full Text]
|
| 41.
|
Rebay, I.,
Fleming, R. J.,
Fehon, R. G.,
Cherbas, L.,
Cherbas, P.,
and Artavanis-Tsakonas, S.
(1991)
Cell
67,
687-699[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Dietz, H. C.,
Cutting, G. R.,
Pyeritz, R. E.,
Maslen, C. L.,
Sakai, L. Y.,
Corson, G. M.,
Puffenberger, E. G.,
Hamosh, A.,
Nanthakumar, E. J.,
Curristin, S. M.,
Stetten, G.,
Meyers, D. A.,
and Francomano, C. A.
(1991)
Nature
352,
337-339[CrossRef][Medline]
|